ReviewBioengineered2017
Production of recombinant coagulation factors: Are humans the best host cells?
Review in Bioengineered, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Recombinant Proteins: Evolution to their Therapeutic Potential.Protein and peptide letters · 2025Review
- A Comparative Review on the Production of Factor VIII in Human and Non-human Hosts.Current pharmaceutical design · 2025Review
- Management of Urgent Bleeding in Patients with Hemophilia A: Focus on the Use of Emicizumab.TH open : companion journal to thrombosis and haemostasis · 2024Review
- Emicizumab as a Promising Form of Therapy for Type A Hemophilia - A Review of Current Knowledge from Clinical Trials.Current protein & peptide science · 2024Review
- Engineering CRISPR/Cas9 for Multiplexed Recombinant Coagulation Factor Production.International journal of molecular sciences · 2022Article
- Hepatitis C Virus Infections in Patients with Hemophilia: Links, Risks and Management.Journal of multidisciplinary healthcare · 2022Review
- Recent Advances in Supramolecular Affinity Separations: Affinity Chromatography and Related Methods.Advances in chromatography · 2021Article
- Polysaccharide-based chromatographic adsorbents for virus purification and viral clearance.Journal of pharmaceutical analysis · 2020Review
- The role of magnetic field in the biopharmaceutical production: Current perspectives.Biotechnology reports (Amsterdam, Netherlands) · 2019Review
- Critical Evaluation of Strategies for the Production of Blood Coagulation Factors in Plant-Based Systems.Frontiers in plant science · 2019Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main treatment option for Hemophilia A/B patients involves the administration of recombinant coagulation factors on-demand or in a prophylactic approach. Despite the safety and efficacy of this replacement therapy, the development of antibodies against the coagulation factor infused, which neutralize the procoagulant activity, is a severe complication. The production of recombinant coagulation factors in human cell lines is an efficient approach to avoid such complication. Human cell lines can produce recombinant proteins with post translation modifications more similar to their natural counterpart, reducing potential immunogenic reactions. This review provides a brief overview of the most important characteristics of recombinant FVIII and FIX products available on the market and the improvements that have recently been achieved by the production using human cell lines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.